Core Insights - Medline Inc. completed a $6.26 billion IPO, marking the largest global IPO of 2025 and receiving strong investor interest on its first trading day [1][3] Group 1: IPO Details - Medline's stock debuted on NASDAQ under the ticker MDLN at an opening price of $35, a nearly 21% increase from the $29 issue price, reaching over $38 during trading, with a peak increase of over 30% [3] - The IPO involved the sale of 216 million shares, with the opening valuation of Medline reaching $47 billion, approximately 40% higher than its valuation during a 2021 acquisition by private equity firms [3][6] - This IPO surpassed the previous record held by CATL's $5.26 billion listing, making it the largest IPO of the year and the largest in the U.S. since Rivian's $13.7 billion IPO in 2021 [3][6] Group 2: Market Impact - Medline's successful IPO contributed to a total IPO fundraising exceeding $46 billion for the year, boosting optimism for the 2026 IPO market, potentially setting the stage for significant listings like SpaceX [4][10] - The IPO received over 10 times the subscription demand, leading to an increase in the number of shares issued from an initial plan of 179 million to 216 million [5] Group 3: Company Background - Medline, founded in 1966, specializes in manufacturing and distributing medical supplies, serving hospitals and clinics with a product range of approximately 335,000 items [6] - The company was acquired by private equity firms Blackstone, Carlyle Group, and Hellman & Friedman in 2021 for up to $34 billion, marking one of the largest leveraged buyouts in history [6] - Medline's CEO, Jim Boyle, aims to position the company as the "Costco of healthcare," emphasizing a strong supply chain and a loyal customer base [7] Group 4: Financial Performance - For the nine months ending September 27, Medline reported a net income of $977 million and revenue of $20.6 billion, compared to $911 million and $18.7 billion in the same period the previous year [7] - The company anticipates a total revenue of $25.5 billion for the full year of 2024 [7] Group 5: Challenges and Strategic Moves - Medline faced challenges in its IPO journey due to uncertainties from U.S. tariff policies and a government shutdown, which delayed its initial plans for a mid-2023 listing [8] - The company has made strategic investments, including a $905 million acquisition of Ecolab Inc.'s surgical solutions business and $1.6 billion in capital expenditures over the past five years to enhance its distribution network [9]
要做医疗保健业Costco，Medline募股62.6亿创今年最大IPO，首秀盘中涨超30%